Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
172 hedge funds and large institutions have $1.62B invested in Esperion Therapeutics in 2019 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 18 closing their positions.
150% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 18
64% more capital invested
Capital invested by funds: $991M → $1.62B (+$631M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
35% more call options, than puts
Call options by funds: $40.9M | Put options by funds: $30.3M
34% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 41
13% more funds holding
Funds holding: 152 → 172 (+20)
2.42% more ownership
Funds ownership: 99.48% → 101.9% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$12.7M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$12.5M |
| 3 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$12.1M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$9.67M |
| 5 |
Millennium Management
New York
|
+$7.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$15.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.4M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$10.1M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$6.67M |
ESPR Hedge Fund Activity: Q4 2019 in Review
172 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2019, worth a combined $1.62B — up 64% from $991M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ESPR positions and 18 closed out — a net gain of 27 holders — while 55 added to existing stakes and 41 trimmed.
The largest buyer was Bellevue Group, adding an estimated $12.7M. The largest seller was Point72 Asset Management, cutting an estimated $18.6M.
- 172 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2019, up from 152 in Q3 2019.
- Funds reported $1.62B of Esperion Therapeutics stock for Q4 2019, up 64% quarter-over-quarter.
- 45 funds opened new Esperion Therapeutics positions in Q4 2019 and 18 closed out, a net change of +27 holders.
- The largest Esperion Therapeutics buyer in Q4 2019 was Bellevue Group, an estimated $12.7M added.
- The largest Esperion Therapeutics seller in Q4 2019 was Point72 Asset Management, an estimated $18.6M sold.
Based on aggregated 13F filings for Q4 2019.